Sellas Life Sciences is trading 4.13% down at $11.15, with no clear company-specific announcement identified to explain the decline.
- Available search results show no clear company-specific announcement on October 6, 2026; the latest identified company news predates the session.
- Biotech-sector weakness may be contributing: XBI is down 2.50% amid broad risk aversion, with no single sector catalyst identified. This does not establish a specific cause for Sellas Life Sciences’ decline.